Out of the 16 patients with evaluable efficacy, 5 (31.2%) patients achieved stable disease, including 2 patients with CRC, 1 patient with KRAS-mutated pancreatic carcinoma, 1 patient with head and neck squamous cell carcinoma, and 1 patient with basal cell carcinoma[64]. Here, KRAS is linked to colorectal carcinoma.